Abstract
Nail psoriasis causes significant aesthetic and functional disabilities. The treatment of nail psoriasis is essential to improve the health outcomes and quality of life among patients. Pain associated with intralesional injections, inadequate penetration into the nail and underlying tissue, poor adherence to therapy, limited efficacy and recurrent relapses are among the many challenging issues with topical therapy. While conventional systemic therapies are still useful and often appropriate for some patients, current evidence indicates that highly selective agents including anti-tumor necrosis factor-alpha, anti-interleukin (IL)-17 and anti-IL-12/23 antibodies that are primarily available for plaque psoriasis and psoriatic arthritis have also demonstrated long-term efficacy in the treatment of nail psoriasis. We report a case of nail psoriasis improved with treatment by risankizumab.